LIGHT/IFN-γ triggers β cells apoptosis via NF-κB/Bcl2-dependent mitochondrial pathway

Quan-You Zheng a, #, Zhao-Hui Cao a, b, c, #, Xiao-Bo Hu b, Gui-Qing Li c, Shi-Fang Dong c, Gui-Lian Xu c, Ke-Qin Zhang a, *

a Department of Nephrology, Southwest Hospital, Third Military Medical University, Chongqing, China
b Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmacy and Biosciences, University of South China, Hengyang, China
c Department of Immunology, School of Basic Medical Sciences, Third Military Medical University, Chongqing, China

Received: December 1, 2015; Accepted: March 8, 2016

Abstract

LIGHT recruits and activates naive T cells in the islets at the onset of diabetes. IFN-γ secreted by activated T lymphocytes is involved in β cell apoptosis. However, whether LIGHT sensitizes IFN-γ-induced β cell destruction remains unclear. In this study, we used the murine β cell line MIN6 and primary islet cells as models for investigating the underlying cellular mechanisms involved in LIGHT/IFN-γ-induced pancreatic β cell destruction. LIGHT and IFN-γ synergistically reduced MIN6 and primary islet cells viability; decreased cell viability was due to apoptosis, as demonstrated by a significant increase in Annexin V+ cell percentage, detected by flow cytometry. In addition to marked increases in cytochrome c release and NF-κB activation, the combination of LIGHT and IFN-γ caused an obvious decrease in expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL, but an increase in expression of the pro-apoptotic proteins Bak and Bax in MIN6 cells. Accordingly, LIGHT deficiency led to a decrease in NF-κB activation and Bak expression, and peri-insulitis in non-obese diabetes mice. Inhibition of NF-κB activation with the specific NF-κB inhibitor, PDTC (pyrrolidine dithiocarbamate), reversed Bcl-xL down-regulation and Bax up-regulation, and led to a significant increase in LIGHT- and IFN-γ-treated cell viability. Moreover, cleaved caspase-9, -3, and PARP (poly (ADP-ribose) polymerase) were observed after LIGHT and IFN-γ treatment. Pretreatment with caspase inhibitors remarkably attenuated LIGHT- and IFN-γ-induced cell apoptosis. Taken together, our results indicate that LIGHT signalling pathway combined with IFN-γ induces β cells apoptosis via an NF-κB/Bcl2-dependent mitochondrial pathway.

Keywords: LIGHT • NF-κB • mitochondrial stress • apoptosis • pancreatic β cell

Introduction

Type 1 diabetes mellitus (T1DM) is an organ-specific autoimmune disorder characterized by chronic inflammation and pancreatic insulin-producing β cell destruction. Pancreatic β cell death is primarily caused by apoptosis [1–3] resulting due to a number of factors. One of the main factors leading to β cell apoptosis is the secretion of the pro-inflammatory cytokine, interferon (IFN)-γ, by autoreactive T lymphocytes and macrophages invading the islets. Moreover, β cell apoptosis is driven by specific combinations of cytokines, such as the combination of IFN-γ and tumour necrosis factor (TNF)-α, but not by a single cytokine alone [4, 5]. The combination and distribution of cytokines vary in different animal models [6, 7]. Further understanding of the apoptotic events activated by the combinations of different cytokines in β cells is necessary for developing individualized therapy strategies to prevent islet β cell destruction in T1DM.

LIGHT (lymphotoxin (LT)-like), exhibits inducible expression and competes with HSV glycoprotein D for herpesvirus entry mediator (HVEM), a receptor expressed by T lymphocytes), is a new member of the TNF superfamily and plays an important role during innate or adaptive immune processes via binding to its receptors, lymphotoxin β receptor (LTβR) or HVEM [8–11]. The LIGHT-LTβR pathway recruits and activates naive T cells in the islets at the onset of diabetes. Early treatment with LTβR-Ig in non-obese diabetic (NOD) mice prevents insulitis and insulin-dependent diabetes mellitus, and LTβR-Ig treatment at a late stage of insulitis also...
dramatically reverses insulitis and prevents diabetes [12–14]. Our previous results showed that LIGHT signalling promotes pro-inflammatory cytokine IFN-γ production [15]. In certain tumour cells, LIGHT binding to LTβR activates the IFN-γ-induced pro-apoptotic pathway [16–19]. However, it is unclear whether LIGHT sensitizes IFN-γ-induced beta cells apoptosis and what are the possible signal transduction events of LIGHT and IFN-γ combinations in beta cell apoptosis.

To further understand the activation of apoptotic pathways by the combination of LIGHT and IFN-γ in beta cells, we used MIN6 insulinoma beta cells and primary islet cells as models. Here, for the first time, these results demonstrate that the LIGHT signalling pathway combined with IFN-γ triggers beta cell apoptosis via an NF-κB/Bcl2-dependent mitochondrial pathway.

Materials and methods

Cell lines and primary islet cells

MIN6 cells are SV40 T-transformed insulinoma beta cells. Primary islet cells were isolated from 5 to 8-week age female NOD mice. The stable MIN6 cells were maintained in 5% CO2 at 37°C. Cells were grown in DMEM culture medium containing 25 mM glucose (Gibco, USA), supplemented with 15% FBS (HyClone, Grand Island, NY, USA), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamine. Cells were treated with 100 ng/ml recombinant mouse IFN-γ (Beyotime Institute of Biotechnology), for 1 h before IFN-γ treatment.

Assessment of cytokine-mediated cytotoxicity by MTT assays

Cells were seeded at an initial density of 30,000/well the day before the experiment, and treated with 100 ng/ml IFN-γ and various concentrations of LIGHT; or 100 ng/ml IFN-γ or 5 μg/ml LIGHT alone or in combination for 48 h; or 100 ng/ml IFN-γ, 10 ng/ml TNF-α, 5 μg/ml LIGHT, or 17.5 ng/ml IL-1β alone, or IL-1β in combination with IFN-γ, TNF-α or LIGHT for 48 h. In some experiments, MIN6 cells were pretreated with the NF-κB inhibitor PDTC, or a broad range caspase inhibitor Z-VAD-FMK (benzyloxycarbonyl-Val-Ala-Asp fluoromethylketone) (Beyotime Institute of Biotechnology), for 1 h before IFN-γ and LIGHT combination treatment for 48 h. MTT assays were performed as described previously [5].

Analysis of cell apoptosis by flow cytometry

To observe morphological changes of live cells under a phase contrast microscope (Olympus 1X71S8-F2, Tokyo, Japan), MIN6 cells were seeded in 96-well microtiter plates and treated with IFN-γ (100 ng/ml) plus LIGHT (5 μg/ml) for 0, 24, and 48 h. To determine cell apoptosis by flow cytometry, cells were treated with media, IFN-γ (100 ng/ml), or LIGHT (5 μg/ml) alone, or in combination for 24 and 48 h. In some experiments, cells were pretreated with caspase inhibitors Z-VAD-FMK for 1 h before LIGHT and IFN-γ treatment. To determine the expression of HVEM and LTβR on MIN6 cells, cells were incubated with antibodies against HVEM (Biologend) and LTβR (Biologend, San Diego, CA, USA), respectively, and analysed by flow cytometry (BD, FACS Canto II). For receptor blockage experiments, cells were pretreated with the recombinant plasmids transfection supernatants containing soluble fusion proteins HVEM-IgGFc, LTβR-IgGFc or N66F-IgGFc, for 1 h before LIGHT and IFN-γ treatment. FACS was performed as described previously [5].

Western blot

MIN6 cells were seeded in six-well plates and treated with the combination of IFN-γ (100 ng/ml) and LIGHT (5 μg/ml) for 0, 0.5, 1, 12, 24 h or for the indicated times. In some experiments, cells were pre-incubated with or without the NF-κB inhibitor PDTC for 1 h and then treated with or without IFN-γ (100 ng/ml) plus LIGHT (5 μg/ml) for 12 h. Antibodies against cytotoxic c (BD Pharmingen, Franklin Lakes, NJ, USA), COX4 (BD Pharmingen), NF-κB p65 (Beyotime Institute of Biotechnology), Bcl-2 (Cell Signalling, Danvers, MA, USA), Bcl-xL (Beyotime Institute of Biotechnology, Beijing, China), Bax (Beyotime Institute of Biotechnology), Bak (Beyotime Institute of Biotechnology), caspase-9 (Beyotime Institute of Biotechnology), PARP (Beyotime Institute of Biotechnology), caspase-3 (Cell Signalling, Danvers, MA, USA) and cleaved caspase-3 (Cell Signalling, Danvers) were used to analyse the expression of proteins by Western blot as previously described [5].

Immunohistochemistry

For immunohistochemistry staining, pancreatic tissues of LIGHT+/- NOD mice and LIGHT/-/- NOD mice were fixed in 4% (w/v) paraformaldehyde, routinely processed and embedded in paraffin. The 3–5 μm sections were stained with a monoclonal rabbit anti-mouse NF-κB p65 antibody, a polyclonal rabbit anti-mouse BAK (Beyotime Institute of Biotechnology), and a monoclonal rabbit anti-mouse BCL-2 (Cell Signalling) respectively.

Analysis of NF-κB activation by the immunofluorescence staining

For immunofluorescence staining of NF-κB in MIN6 cells, cells were grown on coverslips and treated with or without IFN-γ (100 ng/ml) plus LIGHT (5 μg/ml) for 1 h. For immunofluorescence staining of NF-κB in pancreatic tissues of NOD mice, pancreatic tissues were fixed in 4% (w/v) paraformaldehyde, routinely processed and embedded in paraffin. Antibodies against NF-κB p65 (Beyotime Institute of Biotechnology) were used to analyse the activation of NF-κB by immunofluorescence staining.

Measurement of nitrite

MIN6 cells were seeded in 96-well microtiter plates and treated with media, IFN-γ (100 ng/ml) or LIGHT (5 μg/ml) alone or in combination for 48 h. Nitric oxide (NO) level in culture supernatant was determined by measuring the levels of nitrite, a stable by-product of NO by using...
Griess assay (Beyotime Institute of Biotechnology) according to the manufacturer’s suggested protocols.

Intracellular ROS detection

MIN6 cells were seeded at an initial density of 100,000/well 48-well tissue culture plates the day before the experiment, and treated with 100 ng/ml IFN-γ or 5 µg/ml LIGHT alone or in combination for 6 h. The intracellular (reactive oxygen species, ROS) were analysed using a Reactive Oxygen Species Assay Kit (Beyotime Institute of Biotechnology) according to the manufacturer’s suggested protocols. The fluorescence intensity was measured by flow cytometry (BD, FACS Canto II).

Statistics

GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) was used for statistical analysis. Data are presented as mean ± SEM, and statistical analysis of the data was performed by unpaired t-test. Statistically significant differences were assessed at P < 0.05.

Results

LIGHT/IFN-γ synergism inhibits pancreatic beta cell viability

To explore the effect of LIGHT and IFN-γ combination on pancreatic beta cell destruction, cells were exposed to increasing concentrations of LIGHT in the presence of IFN-γ for 48 h. Cell viability decreased in a dose-dependent manner with a peak concentration at 5 µg/ml (Fig. 1A). Although both LIGHT and IFN-γ alone exhibited some inhibition of cell viability, the combination of LIGHT and IFN-γ significantly reduced cell viability (Fig. 1B, IFN-γ versus LIGHT+IFN-γ: P = 0.0061; LIGHT versus LIGHT+IFN-γ: P = 0.0026) as well as the combination of LIGHT and IL-1β (Fig. S1). Moreover, both NO formation and ROS generation was obviously augmented in the presence of LIGHT + IFN-γ (Fig. S2A and B), which might contribute to LIGHT/IFN-γ-mediated cell death. A similar effect was observed on primary islet cells of NOD mice (Fig. 1C). Together, these results indicate that LIGHT and IFN-γ combination treatment synergistically inhibits pancreatic beta cell viability.

LIGHT and IFN-γ treatment triggers MIN6 cells apoptosis

Cell morphology was further assessed under a phase contrast microscope after treatment with the combination of LIGHT and IFN-γ for indicated times. Cell shape changed gradually from sprawling to round, and even floating after treatment for 48 h (Fig. 2A); this change in cell morphology indicated that LIGHT/IFN-γ synergism-mediated cell growth inhibition was because of cell death.

Cell death occurs through a number of mechanisms including apoptosis, necrosis and autophagic cell death. To further investigate which type of cell death was induced by LIGHT and IFN-γ treatment, cells were assayed by flow cytometry through a double labelling assay (Annexin V combined with 7-AAD), which allowed a clear distinction of necrotic or late apoptotic (Annexin V+/7-AAD+) and early apoptotic cells (Annexin V+/7-AAD−). After treatment with the combination of LIGHT and IFN-γ, the early apoptotic cell percentage increased to 28.8% at 24 h and 55.3% at 48 h, but the percentage of late apoptotic or necrotic cells remained below 7.0% (Fig. 2B),
demonstrating that LIGHT and IFN-γ induced cell apoptosis rather than necrosis.

**Combination treatment with LIGHT and IFN-γ induces mitochondrial stress in MIN6 cells**

The classical apoptotic pathways include intrinsic mitochondrial pathways, extrinsic death receptor pathways, and endoplasmic reticulum stress pathways. When combined with TNF-α, IFN-γ secreted by activated T lymphocytes is involved in beta cell apoptosis via the mitochondrial pathway [20]. Moreover, it has been suggested that in certain tumour cells, LIGHT activates an IFN-γ-induced pro-apoptotic pathway through mitochondrial pathways [16–19, 21]. To investigate whether combination treatment with LIGHT and IFN-γ induces mitochondrial stress in beta cells, we determined the effects of LIGHT and IFN-γ treatment on mitochondrial cytochrome c release at the indicated times. Cytosol cytochrome c increased markedly over time after combination treatment of cells with LIGHT and IFN-γ (Fig. 3A), indicating that cytochrome c was released from mitochondrion to cytosol after stimulation with LIGHT and IFN-γ.

**Combination treatment with LIGHT and IFN-γ leads to altered expression of Bcl-2 family members**

The release of cytochrome c from mitochondria is regulated by the Bcl-2 family of proteins [22]. Transcriptional and post-transcriptional modification and protein–protein interactions between members of
the Bcl-2 family determine the fate of cells in this pathway [23, 24]. To explore the effect of LIGHT and IFN-γ treatment on Bcl-2 family members, we assessed the levels of these proteins. After combination treatment with LIGHT and IFN-γ, expression of the anti-apoptotic molecules Bcl-2 and Bcl-xL was obviously down-regulated, while that of the pro-apoptotic molecules Bak and Bax markedly increased over time (Fig. 3B). Consistent with the in vitro results, compared with that of LIGHT+/+ NOD mice, a decrease in Bak expression and peri-insulitis was observed in islets of LIGHT−/− NOD mice (Fig. 3C). These results suggest that LIGHT and IFN-γ treatment enhances cytochrome c release, which may be attributed to a decrease in the ratio of anti-apoptotic molecules, such as Bcl-xL, to pro-apoptotic molecules, such as Bax, subsequently changing mitochondrial membrane structure.

**LIGHT and IFN-γ treatment is involved in NF-κB activation in beta cells**

NF-κB is actively involved in beta cell death [25] and LIGHT-LTβR signalling can activate NF-κB signalling pathways in some cell types [21]. To further investigate the upstream events occurring during mitochondrial stress induced by the combination of LIGHT and IFN-γ treatment, we considered the potential involvement of NF-κB. Cytoplasmic NF-κB p65 protein levels 1 h after cell exposure to LIGHT and IFN-γ were comparable to those of cells in medium (Fig. 4A), but then decreased in a time-dependent manner (Fig. 4B); levels of NF-κB p65 in the nuclei increased markedly (Fig. 4C), suggesting that NF-κB was activated and translocated from cytosol to nucleus. Accordingly, NF-κB p65 expression and activation decreased in LIGHT−/− NOD mice (Fig. 4D and E). These results demonstrate that NF-κB activation is associated with LIGHT and IFN-γ treatment.

**Inhibition of NF-κB activation reduces LIGHT/IFNγ-mediated beta cells apoptosis**

To further assess the relationship between dysregulated expression of anti-apoptotic Bcl-xL and pro-apoptotic Bax and NF-κB activation, cells were pretreated with PDTC (an effective NF-κB inhibitor) for 1 h and then treated with the combination of LIGHT and IFN-γ for 12 h. PDTC treatment reversed cytokine-induced Bcl-xL down-regulation and Bax up-regulation (Fig. 5A), and markedly increased cell viability (Fig. 5B). Moreover, it was interesting that we observed a completely contrast expression pattern of NF-κB with that of Bcl-2, which shows

**Fig. 3** Increased release of cytochrome c and alterations in Bcl-2 family members expression in LIGHT and IFN-γ-induced apoptosis of MIN6 cells. Cells were treated with LIGHT (5 μg/ml) and IFN-γ (100 ng/ml) in combination for the indicated times. Cells were harvested and cytoplasmic protein was extracted. (A) Cytochrome c release was evaluated by Western blot. Cytochrome oxidase subunit IV (COX4), located exclusively in the mitochondria, was used here to confirm whether the cytoplasmic protein fractions included mitochondrial proteins. (B) The expression of Bcl-2, Bcl-xL, Bak and Bax was measured by Western blot. Equal protein loading in each lane was confirmed by probing the blots with anti-β-actin antibody. Data are representative of two-independent experiments. (C) The expression of Bak in primary islets of 20-week-old female LIGHT+/+ and LIGHT−/− NOD mice was measured by immunohistochemistry. Magnification, 200×.
**Fig. 4** NF-κB activation is involved in beta cell destruction. (A) and (B) MIN6 cells were treated with LIGHT (5 μg/ml) or IFN-γ (100 ng/ml) alone, or in combination for the indicated times. Cytoplasmic NF-κB p65 levels were determined by Western blot. Equal protein loading in each lane was confirmed by probing the blots with anti-β-actin antibody. (C) MIN6 cells were treated with LIGHT (5 μg/ml) and IFN-γ (100 ng/ml) in combination for indicated times. The nuclear localization of NF-κB p65 was determined by confocal laser scanning microscopy. Nuclei were stained with Hoechst 33258 solution (5 μg/ml). (D) The expression of NF-κB p65 in primary islets of 20-week-old female LIGHT+/+ and LIGHT−/− NOD mice was measured by immunohistochemistry. Magnification, 200×. (E) The nuclear localization of NF-κB p65 in LIGHT+/+ NOD mice with (peri)insulitis was further determined by confocal laser scanning microscopy. Nuclei were stained with Hoechst 33258 solution (5 μg/ml).
Higher expression of NF-κB while a lower Bcl-2 expression in the periphery of prediabetic NOD mice with insulitis (Fig. 5C). These data suggest that the NF-κB/Bcl-2 pathway is involved in LIGHT and IFN-γ-induced MIN6 cell apoptosis.

**Combination of LIGHT and IFN-γ induces caspase-9 and caspase-3 activation**

Studies have shown that caspase-9 plays crucial roles in the mitochondrial apoptotic pathway, and it is activated by cytochrome c [22, 26]. Cleavage of caspase-3 is one of the downstream events following caspase-9 activation. To investigate if caspase-9 and caspase-3 activation is involved in LIGHT- and IFN-γ-mediated MIN6 cell apoptosis, the expression of cleaved caspase-9 and -3 was analysed by Western blot. As illustrated in Fig. 6A, the combination of LIGHT and IFN-γ caused time-dependent cleavage of caspase-3 and caspase-9. Poly (ADP-ribose) polymerase (PARP), a nuclear polymerase, is one of the main cleavage targets of caspase-3, and served as a marker of cell apoptosis [27]. As shown in Fig. 6B, the cleaved PARP fragment was observed beginning 12 h after cell exposure to the combination of LIGHT and IFN-γ, which may be also associated with high NO formation induced by the LIGHT and IFN-γ treatment (Fig. S2A).

To further verify that caspase protein activation is necessary for LIGHT and IFN-γ-induced MIN6 cell apoptosis, cells were pretreated with Z-VAD-FMK (a broad range caspase inhibitor) before cytokine treatment. As shown in Fig. 6C, LIGHT and IFN-γ-induced cell apoptosis was obviously reduced by Z-VAD-FMK pretreatment (37% versus 20.6% at 24 h), suggesting that caspase activation is required to trigger apoptosis in MIN6 cells.

**Blockage of LIGHT activity with its soluble receptor fusion proteins attenuates LIGHT/IFN-γ synergism-mediated cell apoptosis**

Considering that MIN6 cells express both LTβR and HVEM (Fig. S3), we further distinguished the cytotoxic functions of LIGHT in beta cell apoptosis specifically through HVEM and/or LTβR by pretreating cells with soluble receptor fusion proteins HVEM-Ig or LTβR-Ig before cytokine treatment. Compared with the treatment with N66F-Ig

---

**Fig. 5** Beta cell destruction is NF-κB/Bcl-2 pathway dependent. (A) After pretreatment with or without PDTC (50 μM), an NF-κB inhibitor, for 1 h, MIN6 cells were treated with a combination of IFN-γ and TNF-α for 12 h. The expression of cytoplasmic NF-κB p65, Bcl-xL, and Bax was determined by Western blot. Equal protein loading in all lanes was confirmed by probing the blots with anti-β-actin antibody. (B) After pretreatment with or without PDTC (50 μM) for 1 h, MIN6 cells were treated with or without the LIGHT and IFN-γ combination for 48 h. Cell viability was measured by MTT assay. (C) Reverse expression of p65 and Bcl-2 was observed in primary islets in NOD mice with (peri) insulitis by immunohistochemistry. [Left and right represent different fields in 2 NOD mice with (peri) insulitis]. Magnification, 200×. Data are expressed as mean ± SEM. *P < 0.05. Data are representative of two-independent experiments.

© 2016 The Authors.  
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
(a negative control, which is a Fc fusion protein that does not interfere with LTβR/HVEM/LIGHT interactions), HVEM-Ig or LTβR-Ig treatment caused a remarkable decrease in LIGHT and IFN-γ-mediated MIN6 cell apoptosis (Fig. 7, N66F-IgGFc versus HVEM-IgGFc: 41.8% versus 18.7%, respectively; N66F-IgGFc versus LTβR-IgGFc: 41.8% versus 19.3%, respectively), suggesting that LIGHT plays a role in IFN-γ-mediated MIN6 cell apoptosis, at least partially, via both HVEM and LTβR signalling pathways.

Fig. 6 LIGHT and IFN-γ-induced MIN6 cells apoptosis is caspase-dependent. Cells were treated with IFN-γ (100 ng/ml) and LIGHT (5 μg/ml) in combination for 0.5, 1, 12 and 24 h. The expression of caspase-3, -9, cleaved caspase-3, -9 (A), and cleaved PARP (B) was measured by Western blot. Equal protein loading in all lanes was assessed by probing the blots with β-actin antibody. (C) After pretreatment with or without Z-VAD-FMK (50 μM), a broad range caspase inhibitor, for 1 h, cells were treated with IFN-γ and LIGHT in combination for 48 h. Cells were double stained with annexin V and 7-AAD and then analysed by flow cytometry. Data are representative of three independent experiments.

Fig. 7 Blockage of LIGHT activity by soluble receptor fusion proteins reverses LIGHT/IFN-γ synergism-mediated MIN6 cell apoptosis. After preincubation with soluble receptor fusion proteins HVEM-Ig or LTβR-Ig or N66F-Ig (a negative control, which is an Fc fusion protein that does not interfere with LTβR/HVEM/LIGHT interactions), cells were treated with IFN-γ and LIGHT in combination for 48 h. Cells were double stained with annexin V and 7-AAD and then analysed by flow cytometry. Data are representative of two-independent experiments.
Discussion

Cytokines released by infiltrative T lymphocytes and macrophages are considered the main factors leading to beta cell apoptosis. Moreover, beta cell apoptosis is induced by various combinations of cytokines, with IFN-γ and TNF-α being the most likely cytokines to act synergistically during the inflammation of pancreatic beta cells [28].

Like TNF-α, LIGHT also belongs to the TNF superfamily. LIGHT can enhance IFN-γ secretion by promoting T-cell proliferation and activation, and further increase the cytotoxic activity of T lymphocytes in several autoimmune diseases [29, 30]. LIGHT functions to induce cancer cell apoptosis, especially in the presence of IFN-γ [16–19]. However, the effect and underlying mechanism of the combination of LIGHT and IFN-γ during pancreatic beta cell death are not understood. In this study, we investigated the effect of LIGHT and IFN-γ on pancreatic beta cell apoptosis by using the murine pancreatic beta MIN6 cell line combined with the primary islets cell in NOD mice as a model.

Similar to the effect of TNF-α, LIGHT alone exhibited very mild cytotoxicity for MIN6 cells, but when combined with IFN-γ, LIGHT obviously inhibited cell viability through induction of apoptosis, which is in agreement with the studies in cancer cells [16–19]. In certain tumor cells, LIGHT binding to LTβR activates the IFN-γ-induced pro-apoptotic pathway through mitochondrial pathways [16–19, 21]. Caspase-3, activated by the initiator caspase-9, is an executive caspase, which receives the apoptosis signal from the mitochondria [31]. Our results found that after cells were treated with a combination of LIGHT and IFN-γ, cytochrome c release dramatically increased over time, followed by the activation of caspase-9 and caspase-3. These results demonstrate that intrinsic mitochondrial pathways are involved in LIGHT and IFN-γ-induced MIN6 cell apoptosis.

The mitochondrial apoptotic pathway is tightly controlled by pro- and anti-apoptotic members of the Bcl-2 family [23, 24]. However, the dependence of cytokine-induced beta cell apoptosis on Bcl-2 family proteins is still controversial. In one study, TNF-α and IFN-γ treatment of MIN6 insulinoma cells did not significantly influence Bcl-2 [28]. IL-1β- and IFN-γ-induced beta cell death was demonstrated to be Bax-independent in INS-1 cells and rat islets [32]; Zhang et al. found that Bax is unaltered by LIGHT and IFN-γ treatment in HT-29 cells [17]. However, Grunnet et al. observed an effect of Bax activity on cytokine-induced beta cell apoptosis in INS-1 cells and human islets [6]. Consistent with the results of a study by Grunnet et al., in a previous study, we also found that in TNF-α and IFN-γ-induced NIT-1 cells, Bax expression is remarkably up-regulated, while Bcl-2 expression is gradually down-regulated [4]. In this study, our results show altered expression of Bcl-2 family proteins (including Bcl-2, Bcl-xL, Bax, and Bak) in LIGHT and IFN-γ-treated MIN6 cells and islets of prediabetic NOD mice with peri-insulitis. The increased expression of pro-apoptotic molecules Bax and Bak, and decreased expression of anti-apoptotic molecules Bcl-2 and Bcl-xL may play an intermediate role in LIGHT and IFN-γ-mediated mitochondrial dysfunction in MIN6 cells. The differences among these studies may be related to cell types and the varieties of cytokine combinations.

It remains unclear how LIGHT signalling is involved downstream of the mitochondrial pathway, leading to altered expression of Bcl-2 family members, and ultimately mitochondrial dysfunction. The NF-κB signalling pathway has been shown to regulate expression of multiple genes that play key roles in cell survival or apoptosis [33, 34]. In some cases, NF-κB activation inhibits cell death, but can promote cell death in certain cell types, such as in beta cells [5, 25] and gastric epithelial cells [35]. Our results demonstrate that LIGHT combined with IFN-γ leads to a decrease in cytoplasmic NF-κB p65 levels, but an increase in nuclear NF-κB p65 expression in MIN6 cells, suggesting that NF-κB is activated by IFN-γ and LIGHT
treatment. Pretreatment of MIN6 cells with the NF-κB inhibitor PDTC augmented the rate of Bcl-xL/Bax, and increased cell viability, demonstrating that NF-κB-mediated down-regulation of Bcl-xL and up-regulation of Bax are involved in mediating LIGHT and IFN-γ-induced MIN6 cell apoptosis.

Notably, consistent with the findings observed in LIGHT- and IFN-γ-mediated apoptosis of MDA-MB-231 breast cancer cells [16], although extensive caspase activation of caspases-3, -8 (data not shown) and -9, were observed, treatment with a broad range caspase inhibitor and a caspase-3 inhibitor (data not shown) do not completely block LIGHT/IFN-γ-induced apoptosis in MIN6 cells. It was proposed that a caspase-independent apoptosis pathway might exist in LIGHT- and IFN-γ-mediated MIN6 cell apoptosis, based on our data and that of others [36-38], the existence of such a pathway may warrant further investigation.

Conclusion

In summary, our results show for the first time that LIGHT combined with IFN-γ induces islet beta cells apoptosis via the intrinsic mitochondrial pathway and that this induction is brought about through NF-κB-mediated regulation of anti-apoptotic or pro-apoptotic Bcl-2 family members’ expression (Fig. 8). These results broaden our understanding of anti- and pro-apoptotic signalling induced by cytokines and may provide a basis for the development of future intervention strategies for islet graft failure and T1DM.

References

1. Barthson J, Germano CM, Moore F, et al. Cytokine tumor necrosis factor-α and interferon-γ induce pancreatic β-cell apoptosis through STAT1-mediated Bim protein activation. J Biol Chem. 2011; 286: 39632–43.
2. Kim HS, Lee MS. Role of innate immunity in triggering and tuning of autoimmune diabetes. Curr Mol Med. 2009; 9: 30–44.
3. Gurzov EN, Germano CM, Cunha DA, et al. p53 Up-regulated modulator of apoptosis (PUMA) activation contributes to pancreatic beta-cell apoptosis induced by proinflammatory cytokines and endoplasmic reticulum stress. J Biol Chem. 2010; 285: 19910–20.
4. Cao ZH, Zheng QY, Li GQ, et al. STAT1-mediated down-regulation of Bcl-2 expression is involved in IFN-γ/TNF-α-induced apoptosis in NIT-1 cells. PLoS ONE. 2015; 10: e0120921.
5. Cao ZH, Yin WD, Zheng QY, et al. Caspase-3 is involved in IFN-γ- and TNF-α-mediated MIN6 cells apoptosis via NF-κB/Bcl-2 pathway. Cell Biochem Biophys. 2013; 67: 1239–48.
6. Grunnet LG, Akin R, Tonnesen MF, et al. Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells. Diabetes. 2009; 58: 1807–15.
7. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitls and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009; 5: 219–26.
8. Pasero C, Truneh A, Olive D. Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targeting. Curr Mol Med. 2009; 9: 911–27.
9. Del Rio ML, Lucas CL, Buhler L, et al. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J Leukoc Biol. 2010; 87: 223–35.
10. Cai G, Freeman GJ. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immuno Rev. 2009; 229: 244–58.
11. Fan Z, Yu P, Wang Y, et al. NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood. 2006; 107: 1342–51.
12. Wu Q, Salomon B, Chen M, et al. Reversal of spontaneous autoimmune insulitis in non-obese diabetic mice by soluble lymphotixin receptor. J Exp Med. 2001; 193: 1327–32.
13. Ettinger R, Munson SH, Chao CC, et al. A critical role for lymphotixin-beta receptor in the development of diabetes in nonobese diabetic mice. J Exp Med. 2001; 193: 1333–40.
14. Lee Y, Chin RK, Christiansen P, et al. Recruitment and activation of naive T cells in the islets by lymphotixin beta receptor-dependent tertiary lymphoid structure. Immunity. 2006; 25: 499–509.
15. Xu G, Liu D, Okwor I, et al. LIGHT Is critical for IL-12 production by dendritic cells, optimal CD4+ Th1 cell response, and resistance to Leishmania major. J Immunol. 2007; 179: 6901–9.
16. Zhang M, Guo R, Zhai Y, et al. LIGHT sensitizes IFNγ-mediated apoptosis of MDA-MB-231 breast cancer cells leading to down-regulation of anti-apoptosis Bcl-2 family members. Cancer Lett. 2003; 195: 201–10.

Acknowledgements

We are particularly grateful to Dr Fen Zhang (Department of Endocrine, Tongren Hospital, Beijing, China) for providing the MIN6 cells and Dr. Lixin Zheng (Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA) for providing plasmids coding HVEM-Ig, LTβR-Ig and N66F-Ig. This study was supported by the National Natural Science Foundation of China (81170695 and 81570703), and the Natural Science Foundation of Hunan Province, China (14JJ3104).

Disclosure/conflict of interest

The authors confirm that there are no conflicts of interest.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

Fig. S1. IL-1β in combination with IFN-γ, TNF-α or LIGHT synergistically inhibits beta cell viability.

Fig. S2. The combination of LIGHT and IFN-γ treatment augments NO and intracellular ROS production in MIN6 cells.

Fig. S3. Expression of LTβR and HVEM on MIN6 cells.
17. Zhang MC, Liu HP, Demchik LL, et al. LIGHT sensitizes IFN-gamma-mediated apoptosis of HT-29 human carcinoma cells through both death receptor and mitochondripathways. Cell Res. 2004; 14: 117–24.
18. Li J, Shen F, Wu D, et al. Expression level of Bcl-XL critically affects sensitivity of hepatocellular carcinoma cells to LIGHT-enhanced and interferon-gamma-induced apoptosis. Oncol Rep. 2007; 17: 1067–75.
19. Han B, Wu LQ, Ma X, et al. Synthetic 1,4-anthracenedione analogs induce cytochrome c release, caspase-9, -3, and -8 activities, poly(ADP-ribose) polymerase-1 cleavage and internucleosomal DNA fragmentation in HL-60 cells by a mechanism which involves caspase-2 activation but not Fas signaling. Biochem Pharmacol. 2004; 67: 523–37.
20. Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev. 2003; 17: 2481–95.
21. Kim YS, Nedospasov SA, Liu ZG. TRAF2 plays a key, nonredundant role in LIGHT-lymphotoxin beta receptor signaling. Mol Cell Biol. 2005; 25: 2130–7.
22. Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun. 2003; 304: 437–44.
23. Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 2009; 122: 437–41.
24. Gurzov EN, Ezirik DL. Bcl-2 proteins in diabetes: mitochondrial pathways of beta-cell death and dysfunction. Trends Cell Biol. 2011; 21: 424–31.
25. Melloul D. Role of NF-kappaB in beta-cell death. Biochem Soc Trans. 2008; 36: 334–9.
26. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004; 116: 205–19.
27. Percheflet EM, Wang Y, Weber RL, et al. Light sensitizes IFN-gamma-mediated apoptosis of HT-29 human carcinoma cells through both death receptor and mitochondrial pathways. Cell Res. 2007; 17: 437–50.
28. Suk K, Kim S, Kim YH, et al. IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death. J Immunol. 2001; 166: 4841–9.
29. Tamada K, Shimozaki K, Chapoval AI, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med. 2000; 6: 283–9.
30. Tamada K, Shimozaki K, Chapoval AI, et al. Light, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol. 2000; 164: 4105–10.
31. Simbulan-Rosenthal CM, Rosenthal DS, Iyer S, et al. Involvement of PARP and poly(ADP-ribose) aldon in the early stages of apoptosis and DNA replication. Mol Cell Biochem. 1999; 193: 137–48.
32. Collier JJ, Fueger PT, Hofmeier HE, et al. Pro- and anti-apoptotic proteins regulate apoptosis but do not protect against cytokine-mediated cytotoxicity in rat islets and β-cell lines. Diabetes. 2006; 55: 1398–406.
33. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Ann Rev Immunol. 2000; 18: 621–63.
34. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol. 2002; 3: 221–7.
35. Chu SH, Lim JW, Kim DG, et al. Down-regulation of Bcl-2 is mediated by NF-κB activation in Helicobacter pylori-induced apoptosis of gastric epithelial cells. Scand J Gastroenterol. 2011; 46: 148–55.
36. Denecker G, Verschelden D, Declercq W, et al. Apoptotic and necrotic cell death induced by death domain receptors. Cell Mol Life Sci. 2001; 58: 356–70.
37. Kolenko VM, Uzzo RG, Bukowski R, et al. Caspase-dependent and -independent death pathways in cancer therapy. Apoptosis. 2000; 5: 17–20.
38. Miyazaki K, Yoshida H, Sasaki M, et al. Caspase-independent cell death and mitochondrial disruptions observed in the apaf1-deficient cells. J Biochem. 2001; 129: 963–9.